A novel series of 12 compounds, “C-5-arylidene thiazolidine-2,4-dione derivatives” was constructed, synthesized and characterized using both spectral and non-spectral techniques. The confirmed synthesized compounds were subsequently screened for in vitro aldose reductase inhibitory activity. Among them, compounds R8 and R1 exhibited superior potency against aldose reductase protein with IC50 values of 0.97±0.06 and 1.05 µM±0.11, respectively, as compared to reference drug epalrestat (IC50 value of 1.20±0.09 µM). Additionally, compounds R12 and R9 showed moderate aldose reductase inhibitory activity with IC50 value of 1.35±0.07 and 2.47±0.07 µM, respectively. Furthermore, the top four best active compounds were selected for in vivo anti-hyperglycaemic activity. Results revealed that all the tested compounds significantly decreased blood glucose levels at all time intervals. Computational analysis revealed that all synthesized candidates bound firmly in the protein cavity (PDB id: 4JIR) via hydrogen bonds and steric interaction with the range of docking score -155.60 to -187.58 kcal/mol. The most active compound R8 showed favourable interaction with score of -174.77 kcal/mol compared to the reference drug epalrestat (-132.51 kcal/mol). Predicted in silico toxicity data suggested that the synthesized compounds were inactive and non-toxic against the selected targets. The predicted LD50 analysis of synthesized compounds suggested favourable range of 500-1000 mg/kg of body weight, classifying them into toxicity class 4. These finding results support the potential of TZD derivatives as promising AR inhibitors for managing diabetic complications.